Trial Profile
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CREDENCE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 04 Jan 2024 Results of pooled analysis from CANVAS Program and CREDENCE assessing Treatment effect of canagliflozin for patients on therapy for heart failure, published in the International Journal of Cardiology
- 30 Nov 2023 Results of pooled analysis assessing effects of canagliflozin on clinical outcomes and intermediate markers of subgroups according to population-specific BMI , from the NCT01032629, NCT01989754 and NCT02065791 studies published in the Diabetes, Obesity and Metabolism.
- 12 Nov 2023 Results published in the Circulation